X
All Data
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Ixovex-1
Therapeutic Area: Oncology Product Name: Ixovex-1
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: PsiVac
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 08, 2021
Details:
Under the terms of the parties’ strategic agreement, PsiVac will grant Lonza the exclusive right to cGMP manufacture the Ixovex-1 product.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): NILK-2301
Therapeutic Area: Oncology Product Name: NILK-2301
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: LamKap Bio Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 18, 2020
Details:
Lonza will provide cell line and process development, drug substance manufacturing and drug product services of LamKap's two fully human bispecific antibody products, NILK-2301 and NILK-2401.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
